In neuroblastoma cell proliferation assays, the IC50 values observed with repotrectinib are in the same range as crizotinib, and repotrectinib is able to inhibit ALK phosphorylation over a wide range of ALK mutant variants found in neuroblastoma. This evidence concerns the gene ALK and neuroblastoma.